Profil
Yona Geffen worked as the Chief Executive Officer at Avraham Pharmaceuticals Ltd.
from 2011 to 2016.
Prior to that, Dr. Geffen held the position of Director-Executive Drug Development at BioLineRx Ltd.
and Vice President-Research & Development at Gamida Cell Ltd.
Dr. Geffen obtained graduate and doctorate degrees from Ben-Gurion University of the Negev.
Anciens postes connus de Yona Geffen
| Sociétés | Poste | Fin |
|---|---|---|
Avraham Pharmaceuticals Ltd.
 Avraham Pharmaceuticals Ltd. BiotechnologyHealth Technology Avraham Pharmaceuticals Ltd. develops pharmaceutical products for prevention and treatment of neurodegenerative disorders. Its lead product candidate, Ladostigil is designed to provide treatment for Mild Cognitive Impairment. The firm’s product candidate is a multifunctional compound that combines neuroprotective mechanisms: reducing oxidative stress and microglial activation, and inhibiting proinflamtory cytokines. The company was founded in 2010 by David Warshawsky and is headquartered in Yavneh, Israel. | Directeur Général | 01/12/2016 |
| GAMIDA CELL LTD. | Directeur Technique/Scientifique/R&D | - |
| BIOLINERX LTD. | Corporate Officer/Principal | - |
Formation de Yona Geffen
| Ben-Gurion University of the Negev | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| BIOLINERX LTD. | Health Technology |
| GAMIDA CELL LTD. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Avraham Pharmaceuticals Ltd.
Avraham Pharmaceuticals Ltd. BiotechnologyHealth Technology Avraham Pharmaceuticals Ltd. develops pharmaceutical products for prevention and treatment of neurodegenerative disorders. Its lead product candidate, Ladostigil is designed to provide treatment for Mild Cognitive Impairment. The firm’s product candidate is a multifunctional compound that combines neuroprotective mechanisms: reducing oxidative stress and microglial activation, and inhibiting proinflamtory cytokines. The company was founded in 2010 by David Warshawsky and is headquartered in Yavneh, Israel. | Health Technology |
